CD274 and neoplasm: A new pattern of progression has also been described in patients treated with anti-PD1/PD-L1 mAbs, termed as hyperprogressive disease (defined as a RECIST progression at first evaluation and as a ≥ two-fold increase in the tumor growth rate), and is associated with poorer survival.